Trade Summary

2 months ago, Bodenstedt Matthias, serving as CFO at Moonlake Immunotherapeutics (MLTX), purchased 10,870 shares at $9.09 per share, for a total transaction value of $98,808.00. Following this transaction, Bodenstedt Matthias now holds 627,536 shares of MLTX.

This purchase represents a 2.00% increase in Bodenstedt Matthias's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, October 8, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 9, 2025, 1 day after the trade was made.

Moonlake Immunotherapeutics operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.